Damp Scalp Application Enhances Follicular Delivery of Dutasteride Loaded in Liposomes Compared to Dry Scalp

This abstract introduces androgenic alopecia as the most common form of non-cicatricial alopecia, which predominantly affects men but also has a significant occurrence in women; however, specific research results or conclusions about treatments or mechanisms are not reported in the summary.

This study found that ethosomes containing 30% ethanol slightly improved the targeting of dutasteride to hair follicles in vitro, with a higher targeting factor compared to dried ethosomes and controls after 24 hours on porcine skin.

This review discusses the pharmacokinetics, pharmacodynamics, efficacy, and side effects of dutasteride for androgenetic alopecia, reporting that it may be more effective than finasteride, though potential impacts on male fertility need consideration when prescribing.

This review discusses the current therapies for androgenic alopecia, emphasizing topical formulations like minoxidil and finasteride and exploring the potential of dutasteride-loaded nanocarriers for targeting hair follicles to minimize systemic side effects from oral treatment.

This review study found that vesicular carriers like liposomes, niosomes, invasomes, and transferosomes can enhance drug penetration through follicles, benefiting treatments for alopecia, acne, and infections, as well as potentially facilitating systemic delivery of antihypertensive drugs and insulin.

This study found that dutasteride-loaded transfersomes, compared to traditional liposomes, better target hair follicles by releasing the drug in a more controlled manner, as shown in vitro with enhanced follicular targeting (Tf = 0.32 versus 0.15, p < 0.005) using porcine ear skin.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This review explores the use of skin penetration enhancers like Transcutol® in various formulation systems, discussing their mechanisms and effectiveness in improving transdermal drug delivery without breaching the skin.

This study demonstrated that in a mouse model of androgenic alopecia, PLGA-DUT/siAR@DPCM nanoparticles effectively delivered drugs to hair follicles, suppressed androgen-related targets, promoted cell proliferation, and showed significant therapeutic effects with minimal adverse effects, suggesting their potential for clinical application.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This review examines new formulations for delivering 5-α-reductase inhibitors to improve targeted drug delivery in androgenetic alopecia, but reports no new clinical results.

This study found that a lipid-based nanoparticle formulation with oleic acid for delivering dutasteride showed lower skin permeation compared to a formulation without oleic acid, indicating its potential for targeted dermal delivery.

This study explored using a chitosan oligomer coating for topical delivery of dutasteride-loaded nanostructured lipid carriers, aiming to reduce systemic exposure and cytotoxicity.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This study demonstrates that massage significantly enhances the follicular targeting of dutasteride-loaded nanocapsules, increasing drug accumulation in hair follicles by up to 5 times.

This review compares animal and human skin characteristics in in vitro permeation studies but reports no new results, highlighting variations and the need for better model correlations.

This study found that dutasteride-loaded nanostructured lipid carriers coated with a stearic acid-chitosan oligomer are stable, less cytotoxic, and suitable for topical delivery to promote hair growth.

This study found that minoxidil applied to a damp scalp may increase drug penetration in vitro, potentially improving treatment effectiveness.

This study found that the HPCH-based formulation P-08–016 may facilitate finasteride deposition in the dermis, potentially offering an alternative to systemic therapy by minimizing systemic absorption.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.

This review summarizes drug delivery strategies to hair follicles, highlighting physicochemical factors affecting penetration and the use of stimuli-responsive particulate carriers, but reports no new clinical findings.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

This review summarizes recent advancements in follicular targeting for drug delivery via hair follicles and calls for pilot studies in humans to explore potential clinical applications.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study introduces a novel non-invasive method called "differential stripping" to quantify the penetration of topically applied substances into hair follicles.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.